Pharmacokinetic properties of peramivir after single and multiple intravenous infusion in healthy Chinese volunteers
Background and Objectives Peramivir,an antiviral agent for intravenous administration,is used to treat progressive influenza in patients with serious complications.The present study was designed to determine the pharmacokinetics of single and multiple intravenous infusion of peramivir in healthy Chinese subjects.Methods Single(150 mg,300 mg and 600 mg)and multiple(600 mg)doses of peramivir were intravenously administered to 12 healthy Chinese subjects.There was a 7-day washout period between each dosing period.Blood samples were collected in heparinized tubes at various times.Plasma and urine peramivir was measured using a high performanceliquid chromatography-tandem mass spectrometry method.Subjects and Results Following single doses of peramivir(150 mg,300 mg and 600 mg),the maximum concentration(Cmax)values were 12416±3078 μg/L,23147±3668 μg/L and 44113±3787 μg/L,and the under the plasma concentration–time curve from zero to infinity post dose(AUC∞)values were 24.68±6.48 mg/(h·L–1),47.33±9.22 mg/(h·L–1)and 92.43±12.72 mg/(h·L–1),respectively.The Cmax,AUC0-36 and AUC∞ of peramivir increased proportionally to dose and no trend for accumulation after multiple doses was observed.About 65%of peramivir was excreted unchanged in the urine within the first 24 h.Conclusions Peramivir pharmacokinetics was dose-proportionality with increasing dose,with no accumulation after multiple dosing.Peramivir was generally well tolerated and no serious adverse events occurred.
Ming Zhang Zhan-Zhang Wang Xiao-Jia Ni Li-Zhong Li Yue-Feng Zhang Hao-Yang Lu Huan Peng Wen-Can Huang Ling-Fang Shen Ling-Hui Xiong De-Wei Shang Yu-Guan Wen
The Affiliated Brain Hospital of Guangzhou Medical University(Guangzhou Huiai Hospital),Guangzhou 51 Shanxi Pude Pharmaceuticals Co.,Ltd.,Shanxi 037000,China
国内会议
广州
英文
1-27
2016-12-17（万方平台首次上网日期，不代表论文的发表时间）